These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 26299756)
1. Structural insights into tumor-specific chaperoning activity of gamma synuclein in protecting estrogen receptor alpha 36 and its role in tamoxifen resistance in breast cancer. Panneerselvam M; Muthu K; Ramadas K Mol Biosyst; 2015 Nov; 11(11):2998-3010. PubMed ID: 26299756 [TBL] [Abstract][Full Text] [Related]
2. Synuclein gamma stimulates membrane-initiated estrogen signaling by chaperoning estrogen receptor (ER)-alpha36, a variant of ER-alpha. Shi YE; Chen Y; Dackour R; Potters L; Wang S; Ding Q; Wang Z; Liu YE Am J Pathol; 2010 Aug; 177(2):964-73. PubMed ID: 20595634 [TBL] [Abstract][Full Text] [Related]
3. Molecular dynamic simulations of the tubulin-human gamma synuclein complex: structural insight into the regulatory mechanism involved in inducing resistance against Taxol. Panneerselvam M; Muthu K; Jayaraman M; Sridharan U; Jenardhanan P; Ramadas K Mol Biosyst; 2013 Jun; 9(6):1470-88. PubMed ID: 23532302 [TBL] [Abstract][Full Text] [Related]
4. Dual inhibition of chaperoning process by taxifolin: molecular dynamics simulation study. Verma S; Singh A; Mishra A J Mol Graph Model; 2012 Jul; 37():27-38. PubMed ID: 22609743 [TBL] [Abstract][Full Text] [Related]
5. Gamma synuclein, a novel heat-shock protein-associated chaperone, stimulates ligand-dependent estrogen receptor alpha signaling and mammary tumorigenesis. Jiang Y; Liu YE; Goldberg ID; Shi YE Cancer Res; 2004 Jul; 64(13):4539-46. PubMed ID: 15231664 [TBL] [Abstract][Full Text] [Related]
6. Sphingosine kinase 1 activation by estrogen receptor α36 contributes to tamoxifen resistance in breast cancer. Maczis MA; Maceyka M; Waters MR; Newton J; Singh M; Rigsby MF; Turner TH; Alzubi MA; Harrell JC; Milstien S; Spiegel S J Lipid Res; 2018 Dec; 59(12):2297-2307. PubMed ID: 30315000 [TBL] [Abstract][Full Text] [Related]
7. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635 [TBL] [Abstract][Full Text] [Related]
8. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation. Al-Dhaheri MH; Rowan BG Mol Endocrinol; 2007 Feb; 21(2):439-56. PubMed ID: 17068199 [TBL] [Abstract][Full Text] [Related]
9. Structural insights into selective agonist actions of tamoxifen on human estrogen receptor alpha. Chakraborty S; Biswas PK J Mol Model; 2014 Aug; 20(8):2338. PubMed ID: 25060147 [TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells. Gougelet A; Bouclier C; Marsaud V; Maillard S; Mueller SO; Korach KS; Renoir JM J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):71-81. PubMed ID: 15862952 [TBL] [Abstract][Full Text] [Related]
11. 14-3-3τ drives estrogen receptor loss via ERα36 induction and GATA3 inhibition in breast cancer. Garan LAW; Xiao Y; Lin WC Proc Natl Acad Sci U S A; 2022 Oct; 119(43):e2209211119. PubMed ID: 36252018 [TBL] [Abstract][Full Text] [Related]
12. [Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells]. Meng QW; Zhao CH; Xi YH; Cai L; Sun LC; Sui GJ Ai Zheng; 2006 Aug; 25(8):967-73. PubMed ID: 16965676 [TBL] [Abstract][Full Text] [Related]
13. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Pratt WB; Toft DO Endocr Rev; 1997 Jun; 18(3):306-60. PubMed ID: 9183567 [TBL] [Abstract][Full Text] [Related]
15. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance. Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644 [TBL] [Abstract][Full Text] [Related]
16. Structural insight into the antagonistic action of diarylheptanoid on human estrogen receptor alpha. Geetha Rani Y; Lakshmi BS J Biomol Struct Dyn; 2019 Mar; 37(5):1189-1203. PubMed ID: 29557271 [TBL] [Abstract][Full Text] [Related]
17. Ligand-independent and agonist-mediated degradation of estrogen receptor-alpha in breast carcinoma cells: evidence for distinct degradative pathways. Nonclercq D; Journé F; Body JJ; Leclercq G; Laurent G Mol Cell Endocrinol; 2004 Nov; 227(1-2):53-65. PubMed ID: 15501584 [TBL] [Abstract][Full Text] [Related]
18. Small molecule inhibitor targeting the Hsp70-Bim protein-protein interaction in estrogen receptor-positive breast cancer overcomes tamoxifen resistance. Song T; Zhang H; Zhao Q; Hu Z; Wang Z; Song Y; Zhang Z Breast Cancer Res; 2024 Feb; 26(1):33. PubMed ID: 38409088 [TBL] [Abstract][Full Text] [Related]
19. Synuclein gamma protects HER2 and renders resistance to Hsp90 disruption. Shao Y; Wang B; Shi D; Miao S; Manivel P; Krishna R; Chen Y; Eric Shi Y Mol Oncol; 2014 Dec; 8(8):1521-31. PubMed ID: 24998446 [TBL] [Abstract][Full Text] [Related]